Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for ...

Studies have called into question whether patients with HER2-low breast cancer are being identified and classified accurately.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

In their recent study, Dr. Hurvitz and her research team were interested in determining if T-DXd had improved efficacy for patients with BM compared to other treatments. To approach this, they ...